Skip to main content

Table 3 Relationship between PKM2 expression and clinicopathological features of breast cancer patients with HR-ve versus HR + ve tumors

From: Expression of substance P, neurokinin 1 receptor, Ki-67 and pyruvate kinase M2 in hormone receptor negative breast cancer and evaluation of impact on overall survival

Parameters

HR -ve

HR + ve

Low PKM2

High PKM2

p-value

Low PKM2

High PKM2

p-value

Age (Years)

51.88 ± 12.82

48.96 ± 11.78

0.929

53.08 ± 12.27

51.53 ± 9.54

0.575

Tumor grade

I

II

III

0 (0.0)

7 (16.7)

35 (83.3)

0 (0.0)

2 (8.0)

23 (92.0)

0.466

4 (11.1)

10 (27.8)

22 (61.1)

3 (10.0)

14 (46.7)

13 (43.3)

0.270

Tumor volume (cm 3 )

47.87 ± 67.56

66.64 ± 125.41

0.428

24.97 ± 34.89

34.28 ± 48.29

0.368

TNM Stage

I

II

III

IV

1 (2.5)

14 (35.0)

14 (35.0)

11 (27.5)

2 (8.0)

4 (16.0)

10 (40.0)

9 (36.0)

0.297

3 (8.3)

10 (27.8)

11 (30.6)

12 (33.3)

0 (0.0)

8 (27.6)

9 (31.0)

12 (41.4)

0.532

TNM

I/II

III/IV

15 (37.5)

25 (62.5)

6 (24.0)

19 (76.0)

0.290

13 (36.1)

23 (63.9)

8 (27.6)

21 (72.4)

0.595

T stage

T1

T2

T3

T4

2 (4.8)

22 (52.4)

13 (31.0)

5 (11.9)

3 (12.0)

11 (44.0)

9 (36.0)

2 (8.0)

0.640

5 (13.9)

19 (52.8)

9 (25.0)

3 (8.3)

0 (0.0)

18 (60.0)

10 (33.3)

2 (6.7)

0.197

pT

T1/T2

T3/T4

24 (57.1)

18 (42.9)

14 (56.0)

11 (44.0)

1.000

24 (66.7)

12 (33.3)

18 (60.0)

12 (40.0)

0.615

pN stage

N0

N1

N2

N3

11 (28.2)

13 (33.3)

6 (15.4)

9 (23.1)

7 (28.0)

2 (8.0)

6 (24.0)

10 (40.0)

0.093

12 (34.3)

6 (17.1)

7 (20.0)

10 (28.6)

8 (27.6)

9 (31.0)

6 (20.7)

6 (20.7)

0.602

M stage

M0

M1

29 (72.5)

11 (27.5)

16 (64.0)

9 (36.0)

0.583

24 (66.7)

12 (33.3)

17 (58.6)

12 (41.4)

0.607

Axillary lymph nodes metastasis

Negative

Positive

11 (27.5)

29 (72.5)

7 (28.0)

18 (72.0)

1.000

12 (33.3)

24 (66.7)

9 (30.0)

21 (70.0)

0.797

Lymphatic/vascular invasion

Negative

Positive

15 (38.5)

24 (61.5)

6 (26.1)

17 (73.9)

0.409

16 (45.7)

19 (54.3)

7 (23.3)

23 (76.7)

0.073

HER2 status

Negative

Positive

11 (26.2)

31 (73.2)

17 (68.0)

8 (32.0)

0.001

7 (19.4)

29 (80.6)

24 (80.0)

6 (20.0)

< 0.001

DCIS

Absent

Present

8 (19.0)

34 (81.0)

10 (43.5)

13 (56.5)

0.046

7 (19.4)

29 (80.6)

3 (10.0)

27 (90.0)

0.327

Family History

No

Yes

17 (70.8)

7 (29.2)

15 (68.2)

7 (31.8)

1.000

25 (78.1)

7 (21.9)

26 (89.7)

3 (10.3)

0.307

Ki-67

Low

High

19 (45.2)

23 (54.8)

11 (44.0)

14 (56.0)

1.000

24 (66.7)

12 (33.3)

24 (80.0)

6 (20.0)

0.275

SP

Low

High

24 (57.1)

18 (42.9)

17 (68.0)

8 (32.0)

0.444

26 (72.2)

10 (27.8)

12 (40.0)

18 (60.0)

0.012

NK1R

Low

High

26 (61.9)

16 (38.1)

12 (48.0)

13 (52.0)

0.314

24 (66.7)

12 (33.3)

21 (70.0)

9 (30.0)

0.797

  1. HR: hormone receptor, HER2: human epidermal growth factor receptor 2, DCIS: ductal carcinoma in situ, SP: substance P, NK1R: neurokinin 1 receptor, PKM2: pyruvate kinase M2